Skip to main content

Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.

Publication ,  Journal Article
Seyler, TM; Jinnah, RH; Koman, LA; Marker, DR; Mont, MA; Ulrich, SD; Bhave, A
Published in: J Surg Orthop Adv
2008

The development of knee flexion contractures following total knee arthroplasty is detrimental to a patient's functional capabilities. Despite using aggressive rehabilitative modalities postoperatively, some knee arthroplasty patients do not respond and continue to experience muscle spasms. Botulinum toxin type A has been used as a temporary neuromuscular transmitter blocker to treat muscle spasms in patients with neurological disorders, and it has been utilized as a treatment method for clubfoot. The purpose of this study was to evaluate botulinum toxin type A as a new treatment modality for patients with flexion contractures following total knee arthroplasty that were recalcitrant to standard treatment methods. By 2 years following injections, 9 out of 11 knees achieved extension within 10; of neutral position, and 8 of the 11 maintained this improved range of motion by a mean follow-up of 36 months. There were two failures in patients who had a revision knee arthroplasty, suggesting that this treatment is more effective in patients following primary cases. Based on these results, botulinum toxin type A should be considered as a potential treatment modality, especially in difficult-to-treat cases of knee flexion contracture that are recalcitrant to standard therapy.

Duke Scholars

Published In

J Surg Orthop Adv

ISSN

1548-825X

Publication Date

2008

Volume

17

Issue

4

Start / End Page

231 / 238

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Range of Motion, Articular
  • Postoperative Complications
  • Peptide Fragments
  • Middle Aged
  • Male
  • Knee Joint
  • Injections, Intramuscular
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Seyler, T. M., Jinnah, R. H., Koman, L. A., Marker, D. R., Mont, M. A., Ulrich, S. D., & Bhave, A. (2008). Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. J Surg Orthop Adv, 17(4), 231–238.
Seyler, Thorsten M., Riyaz H. Jinnah, L Andrew Koman, David R. Marker, Michael A. Mont, Slif D. Ulrich, and Anil Bhave. “Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.J Surg Orthop Adv 17, no. 4 (2008): 231–38.
Seyler TM, Jinnah RH, Koman LA, Marker DR, Mont MA, Ulrich SD, et al. Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. J Surg Orthop Adv. 2008;17(4):231–8.
Seyler, Thorsten M., et al. “Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty.J Surg Orthop Adv, vol. 17, no. 4, 2008, pp. 231–38.
Seyler TM, Jinnah RH, Koman LA, Marker DR, Mont MA, Ulrich SD, Bhave A. Botulinum toxin type A injections for the management of flexion contractures following total knee arthroplasty. J Surg Orthop Adv. 2008;17(4):231–238.

Published In

J Surg Orthop Adv

ISSN

1548-825X

Publication Date

2008

Volume

17

Issue

4

Start / End Page

231 / 238

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Range of Motion, Articular
  • Postoperative Complications
  • Peptide Fragments
  • Middle Aged
  • Male
  • Knee Joint
  • Injections, Intramuscular
  • Humans
  • Follow-Up Studies